Vectura & Propeller Health announce collaboration
The companies will develop digitally-connected inhalers to address chronic respiratory diseases.
Vectura Group and Propeller Health have announced a collaboration to develop inhalers that combine Vectura's proven dry powder inhaler (DPI) technology with Propeller's FDA-cleared digital health platform.
Vectura is a leading respiratory pharmaceutical company providing a range of pre-metered foil blister-based dry powder inhalers developed to meet patients' needs in inhalation therapy. The initial focus of the collaboration will be the development of an add-on sensor for Vectura's lever-operated multi-dose inhaler (LOMI). Patients with a Propeller-connected LOMI device will be more engaged with their care and better equipped to understand their disease and improve self-management.
The LOMI device leverages key attributes from Vectura's GyroHaler device:
· Familiar user interface
· Foil blister strips of up to 60 pre-metered doses
· Used blister strip within device
· Key drug delivery components (especially drug contact components) sourced from GyroHaler
Propeller provides the leading digital health platform for asthma and chronic obstructive pulmonary disease (COPD). With information from connected inhalers like LOMI, and its companion analytics and digital interfaces, Propeller helps individuals and their physicians improve the management and control of respiratory disease. The platform is used by more than 40 leading healthcare organizations across the US.
The companies are also discussing additional connected strategies for other proprietary respiratory devices in Vectura's pipeline.
James Ward-Lilley CEO, Vectura, commented: "This announcement demonstrates Vectura's commitment to develop next generation inhalation devices that can help patients manage their respiratory diseases better. Adherence to therapy is one of the major issues driving poor maintenance management of these chronic conditions. There is increasing evidence of the value of intelligent sensor technology significantly enabling a reduction of symptoms, including exacerbations and long term healthcare utilisation costs. This collaboration is a first step towards Vectura embracing a connected solution for all our devices."
David Van Sickle, CEO, Propeller Health, commented: "Digital health has the potential to make respiratory therapies more personal, powerful and convenient for every patient. We are excited to work with the team at Vectura to realize these benefits in a new generation of inhalers."
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance